Herald Investment Management Ltd Buys New Position in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Herald Investment Management Ltd purchased a new position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) during the fourth quarter, Holdings Channel.com reports. The fund purchased 7,417 shares of the medical instruments supplier’s stock, valued at approximately $977,000.

Other institutional investors also recently made changes to their positions in the company. XTX Topco Ltd grew its holdings in Mesa Laboratories by 13.3% during the fourth quarter. XTX Topco Ltd now owns 3,382 shares of the medical instruments supplier’s stock worth $446,000 after acquiring an additional 398 shares during the period. Barclays PLC lifted its stake in Mesa Laboratories by 4.8% during the fourth quarter. Barclays PLC now owns 9,262 shares of the medical instruments supplier’s stock valued at $1,222,000 after purchasing an additional 425 shares during the last quarter. Kennedy Capital Management LLC boosted its holdings in Mesa Laboratories by 13.2% during the fourth quarter. Kennedy Capital Management LLC now owns 74,606 shares of the medical instruments supplier’s stock worth $9,838,000 after buying an additional 8,700 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Mesa Laboratories in the 4th quarter worth $32,677,000. Finally, Resona Asset Management Co. Ltd. acquired a new stake in Mesa Laboratories during the 4th quarter worth about $92,000. 90.60% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Mesa Laboratories

In other news, CEO Gary M. Owens sold 21,000 shares of the stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $123.91, for a total transaction of $2,602,110.00. Following the transaction, the chief executive officer now owns 43,337 shares in the company, valued at $5,369,887.67. This represents a 32.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.40% of the stock is currently owned by company insiders.

Mesa Laboratories Price Performance

Shares of NASDAQ:MLAB opened at $112.01 on Friday. Mesa Laboratories, Inc. has a 12-month low of $83.68 and a 12-month high of $155.12. The company has a market cap of $608.66 million, a P/E ratio of -2.42 and a beta of 0.92. The company has a quick ratio of 0.53, a current ratio of 0.71 and a debt-to-equity ratio of 0.61. The company’s fifty day moving average is $128.51 and its two-hundred day moving average is $127.92.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings data on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.41 by $0.66. Mesa Laboratories had a negative net margin of 104.92% and a positive return on equity of 30.23%. Equities analysts expect that Mesa Laboratories, Inc. will post 8 earnings per share for the current fiscal year.

Mesa Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 16th. Stockholders of record on Friday, May 30th will be issued a dividend of $0.16 per share. The ex-dividend date is Friday, May 30th. This represents a $0.64 annualized dividend and a dividend yield of 0.57%. Mesa Laboratories’s dividend payout ratio is -1.38%.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.